+0.14  (+1%)
Previous Close 12.23
Open 12.2
Price To Book 3.25
Market Cap 536143410
Shares 43,342,232
Volume 84,585
Short Ratio
Av. Daily Volume 58,677

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2019.
Uterine fibroids
Phase 2a Part B has commenced enrolment.
Pre-term labor
Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3.
Phase 3 data due 2H 2019.
Uterine fibroids
Phase 3 trial to be initiated early 2019.
Phase 3 initiation announced November 28, 2018 with data due 4Q 2019.
Nolasiban (OBE001) - IMPLANT 4
Improving IVF outcomes

Latest News

  1. ObsEva SA to Participate in Upcoming Investor Conferences
  2. ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
  3. ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
  4. Hedge Funds Are Betting On ObsEva SA (OBSV)
  5. ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
  6. What Kind Of Investor Owns Most Of ObsEva SA (NASDAQ:OBSV)?
  7. ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
  8. ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
  9. ObsEva SA to Host R&D Investor Day December 7, 2018
  10. ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
  11. Edited Transcript of OBSV.O earnings conference call or presentation 8-Nov-18 1:00pm GMT
  12. ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates
  13. ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
  14. ObsEva SA to Participate in November Investor Conferences
  15. ObsEva Sees Hammer Chart Pattern: Time to Buy?